When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Elliott Crigger, PhD and Christopher Khoury, MSc, MBA
In 2018, the AMA provided a broad framework for evolving AI in health care designed to help realize the benefits it promises for patients and clinicians.
AMA J Ethics. 2019; 21(2):E188-191. doi:
10.1001/amajethics.2019.188.
Shared decision making honors patient autonomy, particularly for preference-sensitive care decisions and even when patients have impaired decision-making capacity.
AMA J Ethics. 2020; 22(5):E358-364. doi:
10.1001/amajethics.2020.358.
AI might improve patient-clinician relationships, but various underlying assumptions will need to be addressed to bring these potential benefits to fruition.
AMA J Ethics. 2020; 22(5):E395-400. doi:
10.1001/amajethics.2020.395.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020; 22(5):E408-415. doi:
10.1001/amajethics.2020.408.